SCHEMBL2003570

SCHEMBL2003570

CCC(C(=O)O)N1C(=O)Cc2cc(Cl)ccc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX3 P56373 1/20 0.42
KDM4E B2RXH2 1/20 0.40
NOTUM Q6P988 2/20 0.40
MAP3K5 Q99683 2/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
ALDH1A1 P00352 1/20 0.37
MDM2 Q00987 1/20 0.37
POLB P06746 1/20 0.37
HSD17B3 P37058 1/20 0.36
KMO O15229 1/20 0.36
MEN1 O00255 1/20 0.36
MAPT P10636 1/20 0.36
ALOX12 P18054 1/20 0.36
KMT2A Q03164 1/20 0.36
PDE5A O76074 1/20 0.36
OPRK1 P41145 1/20 0.36
PDE4D Q08499 1/20 0.36
PTGDR2 Q9Y5Y4 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL662686 0.90 LMNA (0.40) P2RX3KDM4ENOTUMHDAC1HDAC8
SCHEMBL12472190 0.90 LMNA (0.40) P2RX3KDM4ENOTUMHDAC1HDAC8
SCHEMBL9108805 0.87 P2RX3 (0.43) P2RX3NOTUMMAPTPTGDR2
SCHEMBL7450219 0.83 P2RX3 (0.43) P2RX3KDM4ENOTUMHSD17B3MEN1
SCHEMBL7450223 0.83 P2RX3 (0.43) P2RX3KDM4ENOTUMHSD17B3MEN1
SCHEMBL7454667 0.83 P2RX3 (0.43) P2RX3KDM4ENOTUMHSD17B3MEN1
SCHEMBL1902303 0.81 BMPR1A (0.39) PDE5A
SCHEMBL9107932 0.81 CNR2 (0.39) P2RX3NOTUMALDH1A1PTGDR2
SCHEMBL1898876 0.80 BMPR1A (0.40) KDM4EALDH1A1
SCHEMBL14615590 0.78 BMPR1B (0.49) P2RX3NOTUMPOLBMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7964593-B2 Indolone-acetamide derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2011-06-21 US disclosed
US-7645887-B2 2-(5-iodo-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide; epilepsy, epileptogenesis, seizure disorders and convulsion; 2-(5-chloro-2-oxo-2,3-dhydro-1H-indol-1-yl)-N-[6-(hydroxymethyl)cyclohex-3-en-1-yl]acetamide UCB PHARMA, S.A. (BE) 2010-01-12 US disclosed
US-20070043038-A1 Indolone-acetamide derivatives, processes for preparing them and their uses UCB, S.A. (BE) 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043038-A1 Indolone-acetamide derivatives, processes for preparing them and their uses AANAT, TPH2, CYP1A2 P2RX3 852/4885KDM4E 1236/4885NOTUM 1090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.